Imaging Neuroreceptors with Positron Emission Tomography: A New Strategy for Measuring Pharmacological Activity in the Treatment of Schizophrenia
Among the major problems which must be faced in the study of schizophrenia is the lack of an objective set of biological discriptors which can be used to define the syndrome and thus the response to treatment. The advent of positron emission tomography (PET) in the early 1970s offered a new opportunity to directly visualize aspects of cerebral function. PET is a medical imaging technique which measures the concentration of a positron emitting radioisotope in a volume element of tissue. When an appropriately radiolabeled ligand is used, PET provides functional images of the target tissue. Interpretation of these images in a meaningful way is dependent upon an understanding of the underlying biochemistry and physiology of the tissue and characterization of the binding of the radioligand. This involves a knowledge of the process to be traced and the kinetics of that process, since the tomograph only measures but does not attach biological significance to radioactive events.
KeywordsPositron Emission Tomography Cholinergic Receptor Cereb Blood Flow Positron Tomography Positron Emission Tomography Ligand
Unable to display preview. Download preview PDF.
- Buchsbaum MS, Ingvar DH, Kessler R, Waters RN, Cappelletti J, van Kammen DP, King AC, Johnson JL, Manning RG, Flynn RW, Mann LS, Bunney WE Jr, Sokoloff L (1982) Cerebral glucography with positron tomography: use in normal subjects and in patients with schizophrenia. Arch Gen Psychiatry 39:251–259PubMedGoogle Scholar
- Dewey SL, Wolf AP, Fowler JS, Brodie JD, Shiue C-Y, Alavi A, Hiesiger E, Schlyer DJ, Volkow ND, Raulli R, Christman D (1988) The effects of central cholinergic blockade on [I8F]-N-methylspiroperidol binding in human brain using PET. XVI CINP CongressGoogle Scholar
- Farde L, Wiesel F-A, Halldin C, Sedvall G, Nilsson L (1989) Dopamine receptor occupancy and plasma haloperidol levels: in reply. Arch Gen Psychiatry 46: 483–4Google Scholar
- Farkas T, Wolf AP, Fowler J, MacGregor R, Brodie JD, Christman D, Cancro R, Brill R, Goldman A (1981) Regional brain glucose metabolism in schizophrenia. J Cereb Blood Flow Metabol 1 [Suppl 1]:496Google Scholar
- McGeer PL, Eccles JC, McGeer EG (1987) Molecular neurobiology of the mammalian brain. Plenum, New YorkGoogle Scholar
- Smith M, Wolf AP, Brodie JD, Arnett CD, Barouche F, Shiue CY, Fowler JS, Russell JAG, MacGregor RR, Wolkin A, Angrist B, Rotrosen J, Peselow E (1988) Serial 18F-N-Methylspiroperidol PET studies to measure changes in antipsychotic drug D2 receptor occupancy in schizophrenic patients. Biol Psychiatry 23:653–663PubMedCrossRefGoogle Scholar